# Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT03034967** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 614 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Danirixin
- **DRUG:** Danirixin matching placebo
- **DRUG:** Standard of care
- **DRUG:** Rescue medication

## Key facts

- **NCT ID:** NCT03034967
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-25
- **Primary completion:** 2018-10-05
- **Final completion:** 2018-10-05
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03034967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03034967, "Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03034967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*